U.S. Markets open in 7 hrs 37 mins

Bristol-Celgene Deal Faces Hiccup As Officials Examine Psoriasis Drugs

ALLISON GATLIN
Bristol-Celgene Deal Faces Hiccup As Officials Examine Psoriasis Drugs

The FTC is asking for details regarding Bristol's and Celgene's psoriasis treatments ahead of the companies' pending merger deal. The FTC is trying to ensure the merger avoids a monopoly.